EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Gender-affirming hormone therapy, quality of life, and the role of oestradiol and testosterone in transgender individuals

Emma Elisabeth Skovby Petersen iD, Frederika Kiy iD, Ulrik Schiøler Kesmodel iD, Maria Lucia Pop iD, Gry Kjaersdam Telléus iD, Allan Stensballe iD, Jakob Dal, Astrid Højgaard iD, Michael Winterdahl iD

Acta Neuropsychiatrica · 2025

DOI: 10.1017/neu.2025.10018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Neuropsychiatrica, 2025. Verfasst von Emma Elisabeth Skovby Petersen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Sexological Center, Aalborg University Hospital, Stengade 10, Stuen 9000Aalborg, Denmark. Hauptthemen laut MEDLINE: Quality of Life, Testosterone, Estradiol, Transgender Persons. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The present study examines the quality of life (QoL) of transgender and gender-diverse individuals receiving versus not receiving gender-affirming hormone therapy (GAHT) in those assigned male at birth (AMAB) and assigned female at birth (AFAB). It also explores the relationship between QoL and concentrations of oestradiol and testosterone.

Methods

This cross-sectional study used the WHOQOL-BREF questionnaire to assess QoL. Participants were categorised into four groups based on assigned sex at birth (AMAB or AFAB) and GAHT status, with non-GAHT participants serving as controls. MANOVA and t-tests were used to compare QoL between groups, and linear regression analyses examined associations between QoL and oestradiol/testosterone concentrations in AMAB and AFAB participants.

Results

The study included 360 participants: 169 AMAB (143 receiving GAHT and 26 controls) and 191 AFAB (141 receiving GAHT and 50 controls). GAHT recipients had significantly higher QoL than controls in both AMAB (p < 0.01) and AFAB (p = 0.02) groups, particularly in the psychological health domain (D2). AFAB participants reported higher overall QoL than AMAB in both GAHT (p = 0.01) and control (p = 0.04) groups, with significance in the social relationship domain among GAHT participants. No significant relationship was found between oestradiol concentrations and QoL for participants AMAB. However, a significant relationship between testosterone concentrations and QoL was observed only in the social relationship domain (D3) for participant AFAB.

Conclusion

This study highlights the benefits of GAHT for QoL and differences in QoL between individuals AMAB and AFAB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeTestosteroneEstradiolTransgender PersonsGender-Affirming ProceduresHormone Replacement TherapyTranssexualismHumansMaleFemaleCross-Sectional StudiesAdultSurveys and QuestionnairesMiddle AgedYoung Adult

Stichwörter der Autor:innen

Quality of lifegonadal steroid hormonesoestradioltestosteronetransgender persons

Substanzen

TestosteroneEstradiol

Autor:innen und Institutionen

  • Sexological Center, Aalborg University Hospital, Stengade 10, Stuen 9000Aalborg, Denmark.
  • Department of Obstetrics and Gynaecology, Aalborg University Hospital, Aalborg, Denmark.
  • Psychiatry, Aalborg University Hospital, Aalborg, Denmark.
  • Department of Communication and Psychology, Aalborg University, Aalborg, Denmark.
  • Translational Pain Neuroscience and Precision Health, Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.
  • Clinical Cancer Research Unit, Aalborg University Hospital, Aalborg, Denmark.

ORCID-Profile: Emma Elisabeth Skovby Petersen, Frederika Kiy, Ulrik Schiøler Kesmodel, Maria Lucia Pop, Gry Kjaersdam Telléus, Allan Stensballe, Astrid Højgaard, Michael Winterdahl

Zitieren

APA

Petersen, E. E. S., Kiy, F., Kesmodel, U. S., Pop, M. L., Kjaersdam Telléus, G., Stensballe, A., Dal, J., Højgaard, A., & Winterdahl, M. (2025). Gender-affirming hormone therapy, quality of life, and the role of oestradiol and testosterone in transgender individuals. Acta Neuropsychiatrica. https://doi.org/10.1017/neu.2025.10018

Vancouver

Petersen EES, Kiy F, Kesmodel US, Pop ML, Kjaersdam Telléus G, Stensballe A, et al. Gender-affirming hormone therapy, quality of life, and the role of oestradiol and testosterone in transgender individuals. Acta Neuropsychiatrica. 2025. doi:10.1017/neu.2025.10018

BibTeX
@article{Petersen2025,
  author = {Petersen, Emma Elisabeth Skovby and Kiy, Frederika and Kesmodel, Ulrik Schiøler and Pop, Maria Lucia and Kjaersdam Telléus, Gry and Stensballe, Allan and Dal, Jakob and Højgaard, Astrid and Winterdahl, Michael},
  title = {Gender-affirming hormone therapy, quality of life, and the role of oestradiol and testosterone in transgender individuals},
  journal = {Acta Neuropsychiatrica},
  year = {2025},
  doi = {10.1017/neu.2025.10018}
}
Kostenlos starten →